The May (2026) issue of the Journal of Cardiac Failure shines a spotlight on infiltrative and inflammatory cardiomyopathies, including amyloidosis, sarcoidosis, and myocarditis, and the rapidly evolving science shaping their future.
On this episode of the Heart Failure Beat, guest editors Drs. Nisha A. Gilotra, Mathew Maurer and Emer Joyce discuss the diagnostic challenges these patients face, the rise of non-biopsy diagnosis, emerging targeted therapies, AI-driven diagnostics, multidisciplinary care models, and why earlier recognition is transforming outcomes.
The conversation also explores how the field is evolving for trainees, researchers, and patients alike, and why this special focus issue may represent a launchpad for innovation across heart failure care.
Listen below and subscribe: Apple Podcasts, Amazon Music, Spotify, Podcast Home
Tune into highlight clips on YouTube
References, Links and Disclosures
Mathew Maurer, MD: Grant support from NIH R01HL177670, R01AG093132 and R01AG081582; grants and personal fees from Alnylam, Pfizer, BridgeBio, Intellia and Ionis; and personal fees from AstraZeneca and Bayer.
Emer Joyce, MD, PhD: Speaker / Honoraria fees; Travel; Advisory Board: Bayer, Alnylam, Pfizer, AstraZeneca, Steering Committee Member: FIRE-1, PI: ACT-EARLY, TRITON-CM, ATTRibute-CM
May (2026) issue of the Journal of Cardiac Failure
Disclaimer
The opinions and perspectives expressed in this episode are those of the individual guests and hosts and do not necessarily reflect the official views of the Heart Failure Society of America (HFSA). This discussion is intended for educational purposes only and does not constitute medical advice or an endorsement of any specific pharmaceutical product or therapy. HFSA does not endorse one medication over another. Patients should consult their healthcare professionals for individualized evaluation and treatment decisions.